Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer vaccines - Marker Therapeutics Inc

Drug Profile

Research programme: cancer vaccines - Marker Therapeutics Inc

Alternative Names: AdhTAP; AdhTAP(OS-1); HER2/Neu T-cell vaccine - Marker Therapeutics Inc; TPIV 120; TPIV 130

Latest Information Update: 31 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TapImmune
  • Developer Marker Therapeutics Inc
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 15 Mar 2019 Marker Therapeutics has patent protection and pending patents for PolyStartTM technology in USA
  • 17 Oct 2018 TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc., while its subsidiary changed the name to Marker Cell Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top